12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GSK961081: Phase IIb data

A double-blind, placebo- and active-controlled, international Phase IIb trial in 436 patients with moderate to severe COPD showed that all doses of GSK961081 met the primary endpoint of improving mean morning trough FEV1 from baseline to day 29 vs. placebo (p<=0.001 for all). Specifically, once-daily 100, 400 and 800 µg GSK961081 led to mean differences from placebo...

Read the full 261 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >